Provided by Tiger Trade Technology Pte. Ltd.

Alnylam Pharmaceuticals

237.10
+0.54000.23%
Pre-market: 236.99-0.1100-0.05%07:57 EDT
Volume:1.85M
Turnover:433.72M
Market Cap:31.64B
PE:42.19
High:239.08
Open:224.47
Low:223.61
Close:236.56
52wk High:495.55
52wk Low:197.81
Shares:133.43M
Float Shares:133.16M
Volume Ratio:1.15
T/O Rate:1.39%
Dividend:- -
Dividend Rate:- -
EPS(TTM):5.62
EPS(LYR):2.33
ROE:96.55%
ROA:12.34%
PB:23.36
PE(LYR):101.76

Loading ...

NASDAQ Top and Bottom Performing Stocks at About 02:45 P.m. EDT on 2026-07-10

Reuters
·
Jul 11

Movement Alert|Alnylam Pharmaceuticals Falls 5.08% in Regular Trading, Trading at $296.89

Market Focus
·
Jul 11

Alnylam Pharmaceuticals is Maintained at Equal-weight by Morgan Stanley

Dow Jones
·
Jul 10

Alnylam Pharmaceuticals (ALNY) Could Be 28% Undervalued Following Rival ATTR Trial Failure

Simply Wall St.
·
Jul 10

Analysts Offer Insights on Healthcare Companies: Simulations Plus (SLP), Alnylam Pharma (ALNY) and Revolution Medicines (RVMD)

TIPRANKS
·
Jul 10

Alnylam, Bridgebio Gain from Astrazeneca-ionis Drug Missing Target

Dow Jones
·
Jul 10

Raymond James Adjusts Price Target on Alnylam Pharmaceuticals to $468 From $420, Maintains Outperform Rating

MT Newswires Live
·
Jul 09

AstraZeneca PLC Stock (AZN) Moved Down by 6.72% on Jul 9: A Full Analysis

TradingKey
·
Jul 09

NASDAQ Top and Bottom Performing Stocks at About 11:01 A.m. EDT on 2026-07-09

Reuters
·
Jul 09

Lumentum, Applied Materials, Corning, Astrazeneca, and More Stocks That Explain Today's Market

Dow Jones
·
Jul 09

Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY) and Eli Lilly & Co (LLY)

TIPRANKS
·
Jul 09

Alnylam Pharmaceuticals up over 12%, on Pace for Largest Percent Increase Since July 2025

Dow Jones
·
Jul 09

Movement Alert|Alnylam Pharmaceuticals Rises 15.34% in Regular Trading, Competitor AstraZeneca Late-Stage Cardiac Trial Failure Clears Competitive Path

Market Focus
·
Jul 09

Alnylam Pharmaceuticals Shares Jump 15.5% After Astrazeneca's Nerve Disease Drug Wainua Fails Late-stage Heart Disease Trial

THOMSON REUTERS
·
Jul 09

S&P 500 Futures Climb in Premarket Trading; Alnylam Pharmaceuticals, Bridgebio Pharma Lead

Dow Jones
·
Jul 09

Premarket Movers | ALNY Jumps Nearly 16% as Rival Drug Wainua Flops Critical Trial

Tiger Newspress
·
Jul 09

Bridgebio Pharma Shares Rise 9.9%

THOMSON REUTERS
·
Jul 09

Movement Alert|Alnylam Pharmaceuticals Rises 6.11% in Pre-Market Trading, Trading at $336.95

Market Focus
·
Jul 09

Movement Alert|Alnylam Pharmaceuticals Rises 5.1% Overnight, Trading at $340.0

Market Focus
·
Jul 09

Astrazeneca's Wainua Fails Key Heart Disease Trial, Shares Tumble

Reuters
·
Jul 09